For Review Only A comprehensive review of the compounds for the prevention or treatment of oral mucositis in patients undergoing radio-chemotherapy: Part 1 Journal: Current Pharmaceutical Biotechnology Manuscript ID: CPB-2015-0074 Manuscript Type: Invited Review Date Submitted by the Author: 27-Jun-2015 Complete List of Authors: Panahi, Yunes; Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Shadboorestan, Amir Ahmadi, Amirhossein; Faculty of Pharmacy, Mazandaran University of Medical Sciences, Ghobadi, Roja Keywords: oncology, oral mucositis, oral ulceration, radiotherapy, chemotherapy, cancer https://mc04.manuscriptcentral.com/cpb Current Pharmaceutical Biotechnology
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
For Review O
nly
A comprehensive review of the compounds for the
prevention or treatment of oral mucositis in patients undergoing radio-chemotherapy: Part 1
Journal: Current Pharmaceutical Biotechnology
Manuscript ID: CPB-2015-0074
Manuscript Type: Invited Review
Date Submitted by the Author: 27-Jun-2015
Complete List of Authors: Panahi, Yunes; Chemical Injuries Research Center, Baqiyatallah University
of Medical Sciences, Shadboorestan, Amir Ahmadi, Amirhossein; Faculty of Pharmacy, Mazandaran University of Medical Sciences, Ghobadi, Roja
Keywords: oncology, oral mucositis, oral ulceration, radiotherapy, chemotherapy, cancer
https://mc04.manuscriptcentral.com/cpb
Current Pharmaceutical Biotechnology
For Review O
nly
1
Abstract
Oral mucositis is considered a painful condition that occurs in cancer patients after radiotherapy
and chemotherapy. It appears as small patches to areas of extensive ulceration and hemorrhage in
the oral mucosa. Oral mucositis is a major clinical challenge in oncology, characterized by pain
and inflammation of the mucous membrane surface that particularly result from radiation therapy
for head and neck cancer or from chemotherapeutic agents. Manifestations range from a burning
sensation to ulcer formation that affect patients’ quality of life by producing pain and discomfort
on swallowing, ultimately leading to malnutrition and dehydration. Despite its frequency and the
severity of its clinical manifestations, no effective treatment exists for mucositis. Various types
of compounds have been used for the treatment of oral mucositis or to reduce the severity of its
symptoms. This comprehensive review aims to update the knowledge regarding the various
compounds that are effective against mucositis following radiotherapy and/or chemotherapy.
1. Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in globocan 2012. Int J Cancer 136, 359–386 (2015).
2. Agnihotri AK, Bahorun T, Aruoma OI. Cancer: Global health perspectives. Arch Med Biomed Res
1, 1-9 (2014). 3. Lockhart AC, Reed CE, Decker PA et al. Phase ii study of neoadjuvant therapy with docetaxel,
cisplatin, panitumumab, and radiation therapy followed by surgery in patients with locally advanced adenocarcinoma of the distal esophagus (acosogz4051)†
. Annals of Oncology 25, 1039–1044 (2014).
4. Lawrence TS, Haffty BG, Harris JR. Milestones in the use of combined-modality radiation therapy and chemotherapy. Journal of clinical oncology 32(12), 1173-1179 (2014).
5. Devita T, Chu E. A history of cancer chemotherapy. Cancer Res 63(21), 8643-8653 (2008). 6. Delaney G, Jacob S, Featherstone C, Barton M. The role of radiotherapy in cancer treatment
estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer 104(6), 1129-1137 (2005).
7. Lalla RV, Saunders DP, Peterson DE. Chemotherapy or radiation-induced oral mucositis. Dent
Clin N Am 58, 341–349 (2014). 8. Rao-Naidu AU, Ramana GV, Rani PU, Mohan IK, Suman A, Roy P. Chemotherapy-induced and/or
radiation therapy-induced oral mucositis-complicating the treatment of cancer. Neoplasia 6(5), 423 – 431 (2004).
9. Redding SW. Cancer therapy-related oral mucositis. Journal of Dental Education 69(8), 919-929 (2005).
10. Sonis ST. Pathobiology of oral mucositis: Novel insights and opportunities. J Support Oncol 5(9), 3–11 (2007).
11. Harris DJ. Cancer treatment-induced mucositis pain: Strategies for assessment and management. Therapeutics and Clinical Risk Management 2(3), 251–258 (2006).
12. Köstler WJ, Hejna M, Wenzel C, Zielinski CC. Oral mucositis complicating chemotherapy and/or radiotherapy: Options for prevention and treatment. CA Cancer J Clin 51, 290-315 (2001).
13. Sonis ST. Oral mucositis. Anti-Cancer Drugs 22, 607–612 (2011). 14. Campos M, Campos CN, Aarestrup FM, Aarestrup BJV. Oral mucositis in cancer treatment:
Natural history, prevention and treatment (review). Molecular and clinical oncology 2, 337-340 (2014).
15. Silverman S. Diagnosis and management of oral mucositis. The journal of supportive oncology
5(2), 13-21 (2007). 16. Sonis ST. A biological approach to mucositis. J Support Oncol 2, 21–36 (2004). 17. Yarom N, Ariyawardana A, Hovan A et al. Systematic review of natural agents for the
management of oral mucositis in cancer patients. Support Care Cancer 21, 3209–3221 (2013). 18. Sonis ST. Mucositis: The impact, biology and therapeutic opportunities of oral mucositis. Oral
Oncology 45, 1015–1020 (2009). 19. Rahal A, Kumar A, Singh V et al. Oxidative stress, prooxidants, and antioxidants: The interplay.
Biomed research international 2014, 1-19 (2014). 20. Surh YJ, Chun KS, Cha HH, Han SS, Keum YS, Park KK. Molecular mechanisms underlying
chemopreventive activities of anti-inflammatory phytochemicals: Down-regulation of cox-2 and inos through suppression of nf-κb activation. Mutation Research 480–481, 243–268 (2001).
21. The cell molecular approach. Cooper GM, Hausman RE (Ed.^(Eds). ASM Press, Washington (2009).
22. Singh BN, Singh HB, Singh A, Naqvi AH, Singh BR. Dietary phytochemicals alter epigenetic events and signaling pathways for inhibition of metastasis cascade. Cancer Metastasis Rev 33, 41–85 (2014).
23. Lu Z, Xu S. Erk1/2 map kinases in cell survival and apoptosis. IUBMB Life 58(11), 621 – 631 (2006).
24. Santarpia L, Lippman SL, El-Naggar AK. Targeting the mitogen-activated protein kinase ras-raf signaling pathway in cancer therapy. Expert Opin Ther Targets 16(1), 103–119 (2012).
25. Drabsch Y, Ten-Dijke P. Tgf-β signaling in breast cancer cell invasion and bone metastasis. J
Mammary Gland Biol Neoplasia 16, 97–108 (2011). 26. Sengupta S, Jana S, Bhattacharyy A. Tgf-β-smad2 dependent activation of cdc 25a plays an
important role in cell proliferation through nfat activation in metastatic breast cancer cells. Cellular Signalling 26 240–252 (2014).
27. Han G, Bian L, Li F et al. Preventive and therapeutic effects of smad7 on radiation-induced oral mucositis. Nat Med 19, 421–428 (2013).
28. Bian L, Han G, Zhao CW, Garl PJ, Wang XJ. The role of smad7 in oral mucositis. Protein&Cell, 1-10 (2015).
29. Iglesias-Bartolome R, Patel V, Cotrim A et al. Mtor inhibition prevents epithelial stem cell senescence and protects from radiation-induced mcositis. Cell Stem Cell 11, 401–414 (2012).
30. Eilers J, Million R. Clinical update: Prevention and management of oral mucositis in patients with cancer Seminars in Oncology Nursing 27(4), 1-16 (2011).
31. Sonis S, Costa JW, Evitts SM, Lindquist LE, Nicolson M. Effect of epidermal growth factor on ulcerative mucositis in hamsters that receive common chemotherapy. Oral Surg Oral Med Oral
Pathol 74, 749 – 755 (1992). 32. Eilers J, Million R. Prevention and management of oral mucositis in patients with cancer
Seminars in Oncology Nursing 23(3 ), 201-212 (2007). 33. Bogunia-Kubik K, Polak M, Lange A. Tnf polymorphisms are associated with toxic but not with
agvhd complications in the recipients of allogeneic sibling haematopoietic stem cell transplantation. Bone Marrow Transplant 32, 617–622 (2003).
34. Rodrıguez-Caballero A, Torres-Lagares D, Robles-Garcıa M, Pachon-Ibanez J, Gonzaez-Padillac D, Gutierrez-Pereza JL. Cancer treatment-induced oral mucositis: A critical review. Int J Oral
Maxillofac Surg 41, 225–238 (2012). 35. Harris DJ, Eilers J, Harriman A, Cashavelly BJ, Maxwell C. Putting evidence into practice®:
Evidence-based interventions for the management of oral mucositis. Clinical Journal of Oncology
Nursing 12(1), 141-152 (2008). 36. Wright J, Feld R, Knox J. Chemotherapy-induced oral mucositis: New approaches to prevention
and management. Expert Opin Drug Saf 4(2), 193-200 (2005). 37. V.Lall R, Bowen J, Barasch A et al. Mascc/isoo clinical practice guidelines for the management of
mucositis secondary to cancer therapy. Cancer, 1453-1461 (2014). 38. B.Mcguire D, S.Fulton J, Park J et al. Systematic review of basic oral care for the management of
oral mucositis in cancer patients. Support Care Cancer 21, 3165–3177 (2013). 39. Quinn B. Efficacy of a supersaturated calcium phosphate oral rinse for the prevention and
treatment of oral mucositis in patients receiving high-dose cancer therapy: A review of current data. European Journal of Cancer Care 22, 564–579 (2013).
40. Quinn B, Davies M, Horn J et al. Mouth care guidance and support in cancer and palliative care. (2012).
41. Stokman MA, Burlage FR, Spijkervet FKL. The effect of a calcium phosphate mouth rinse on (chemo) radiation induced oral mucositis in head and neck cancer patients: A prospective
study. Int J Dent Hygiene 10, 175--180 (2012). 42. Markiewicz M, Dzierzak-Mietla M, & AFPZ, Koclega A, Kruszelnicka M, Kyrcz-Krzemien S.
Treating oral mucositis with a supersaturated calcium phosphate rinse: Comparison with control in patients undergoing allogeneic hematopoietic stem cell transplantation. Support Care Cancer
20, 2223–2229 (2012). 43. Berry AM. A comparison of listerine® and sodium bicarbonate oral cleansing solutions on
dental plaque colonisation and incidence of ventilator associated pneumonia in mechanically ventilated patients: A randomised control trial. Intensive and Critical Care Nursing 29, 275—281
(2013). 44. Choi SE, Kim HS. Sodium bicarbonate solution versus chlorhexidine mouthwash in oral care of
acute leukemia patients undergoing induction chemotherapy: A randomized
controlled trial. Asian Nursing Research 6, 60-66 (2012). 45. Ozden D, Turk G, Duger C, K.Guler E, Tok F, Gulsoy Z. Effects of oral care solutions on mucous
membrane integrity and bacterial colonization. British Association of Critical Care Nurses 19(2), 78-86 (2013).
46. Soares AF, Aquino AR, Carvalho CH, Nonaka CF, Almeida D, Pinto LP. Frequency of oral mucositis and microbiological analysis in children with acute lymphoblastic leukemia treated with 0.12% chlorhexidine gluconate. Braz Dent J 22(4), 312-316 (2011).
47. Diaz-Sanchez RM, Pachón-Ibáñez J, Marín-Conde F, Rodríguez-Caballero Á, Gutierrez-Perez JL, Torres-Lagares D. Double-blind, randomized pilot study of bioadhesive chlorhexidine gel in the prevention and treatment of mucositis induced by chemoradiotherapy of head and neck cancer. Med Oral Patol Oral Cir Bucal article in press, 1-8 (2015).
48. Sritrairat N, Nukul N, Inthasame P et al. Antifungal activity of lawsone methyl ether in comparison with chlorhexidine. J Oral Pathol Med 40(1), 90–96 (2011).
49. Rao NG, Han G, Greene JN et al. Effect of prophylactic fluconazole on oral mucositis and candidiasis during radiation therapy for head-and-neck cancer. Practical Radiation Oncology 3, 229–233 (2013).
50. Giles FJ, Rodriguez R, Weisdorf D et al. A phase iii, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy. Leukemia Research 28, 559–565 (2004).
51. Trotti A, Garden A, Warde P et al. A multinational, randomized phase iii trial of iseganan hcl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. Int J Radiat Oncol Biol Phys 58(3), 674-681 (2004).
52. Gordon YJ, Romanowski EG. A review of antimicrobial peptides and their therapeutic potential as anti-infective drugs. Curr Eye Res 30(7), 505–515 (2005).
53. Durani P, Leaper D. Povidone-iodine: Use in hand disinfection, skin preparation and antiseptic irrigation. Int Wound J 5(3), 376-387 (2008).
54. Adamietz IA, Rahn R, Bottcher HD, Schafer V, Reimer K, Fleischer W. Prophylaxis with povidone-iodine against induction of oral mucositis by radiochemotherapy. Support Care Cancer 6, 373–377 (1998).
55. Rahn R, Adamietz IA, Boettcher HD, Schaefer V, Reimer K, Fleischer W. Povidone-iodine to prevent mucositis in patients during antineoplastic radiochemotherapy. Dermatology 195, 57–61 (1997).
56. Dinwiddie MT, Terry PD, Chen J. Recent evidence regarding triclosan and cancer risk. Int J
Environ Res Public Health 11(2), 2209-2217 (2014). 57. Campbell L, Zirwas MJ. Triclosan. Dermatitis 17(4), 204–207 (2006). 58. Satheeshkumar PS, Chamba MS, Balan A, Sreelatha KT, Bhatathiri VN, Bose T. Effectiveness of
triclosan in the management of radiation-induced oral mucositis: A randomized clinical trial. J Cancer Res Ther 6(4), 466-472 (2010).
59. Oliveira-Leite AMD, Lemos-Miguel MA, Silva-Peixoto R, Soares-Rosado A, Trajano-Silva J, Flosi-Paschoalin VM. Microbiological, technological and therapeutic properties of kefir: A natural probiotic beverage. Brazilian Journal of Microbiology 44, 2, () 44(2), 341-349 (2013).
60. Topuz E, Derin D, Can G et al. Effect of oral administration of kefir on serum proinflammatory cytokines on 5-fu induced oral mucositis in patients with colorectal cancer. Invest New Drugs
26(6), 567-572 (2008). 61. Donnelly JP, Bellm LA, Epstein JB, Sonis ST, Symonds RP. Antimicrobial therapy to prevent or
treat oral mucositis. The Lancet Infectious Diseases 3, 405-412 (2003). 62. Ngeow WC, Chai WL, Zain RB. Management of radiation therapy-induced mucositis in head and
neck cancer patients. Part ii: Supportive treatments. Oncology Reviews 2(3), 164-182 (2008). 63. Araújo AaD, Varela H, Medeiros CaCXD, Brito GaDC, Lima KCD, Moura LMD. Azilsartan reduced
tnf-α and il-1β levels, increased il-10 levels and upregulated vegf, fgf, kgf, and tgf-α in an oral mucositis model. PLoS One 10(2), 1-16 (2015).
64. Haagen J, Krohn H, Röllig S, Schmidt M, Wolfram K, Dörr W. Effect of selective inhibitors of inflammation on oral mucositis: Preclinical studies. Radiotherapy and Oncology 92, 472–476 (2009).
65. Satheeshkumar PS, Mohan MP. A new alimentary tract mucosal inflammation model and a possibility of receptor targeted therapy in tissue reactions in cytotoxic therapy. Oral Oncology
51(3), 15-16 (2015). 66. Epstein JB, Silverman S, Paggiarino DA et al. Benzydamine hcl for prophylaxis of radiation-
induced oral mucositis results from a multicenter, randomized, double-blind, placebo-controlled clinical trial. Cancer 92, 875–885 (2001).
67. Karavana SY, Sezer B, Guneri P et al. Efficacy of topical benzydamine hydrochloride gel on oral mucosal ulcers: An in vivo animal study. Int. J. Oral Maxillofac. Surg 40, 973–978 (2011).
68. Sheibani KM, Mafi AR, Moghaddam S, Taslimi F, Amiran A, Ameri A. Efficacy of benzydamine oral rinse in prevention and management of radiation-induced oral mucositis: A double-blind placebo-controlled randomized clinical trial. Asia-Pacific Journal of Clinical Oncology 11, 22–27 (2015).
69. Lalla RV, Sonis ST, Peterson DE. Management of oral mucositis in patients who have cancer. Dent Clin North Am 52, 61–77 (2008).
70. Veness MJ, Foroudi F, Gebski V et al. Use of topical misoprostol to reduce radiation-induced mucositis: Results of a randomized, double-blind, placebo-controlled trial. Australas Radiol 50, 468–474 (2006).
71. Lalla RV, Gordon GB, Schubert M et al. A randomized, double-blind, placebo-controlled trial of misoprostol for oral mucositis secondary to high-dose chemotherapy. Support Care Cancer 20, 1797–1804 (2012).
72. Duenas-Gonzalez A, Sobrevilla-Calvo P, Frias-Mendivil M et al. Misoprostol prophylaxis for high-dose chemotherapy-induced mucositis: A randomized double-blind study. Bone Marrow
73. Rothwell BR, Spektor WS. Palliation of radiation-related mucositis. Spec Care Dentist 10, 21–25 (1990).
74. Barker G, Loftus L, Cuddy P, Barker B. The effects of sucralfate suspension and diphenhydramine syrup plus kaolin-pectin on radiotherapy-induced mucositis. Oral Surg Oral Med Oral Pathol 71, 288–293 (1991).
75. Carnel SB, Blakeslee DB, Oswald SG, Barnes M. Treatment of radiation- and chemotherapy-induced stomatitis. Otolaryngol Head Neck Surg 102, 326–330 (1990).
76. Lalla RV, Pilbeam CC, Walsh SJ, Sonis ST, Keefe DM, Peterson DE. Role of the cyclooxygenase pathway in chemotherapy-induced oral mucositis: A pilot study. Support Care Cancer 18(1), 95-103 (2010).
77. Lalla RV, Choquette LE, Curley KF et al. Randomized double-blind placebo-controlled trial of celecoxib for oral mucositis in patients receiving radiation therapy for head and neck cancer. Oral Oncology 50, 1098–1103 (2014).
78. Porteder H, Rausch E, Kment G, Watzek G, Matejka M, Sinzinger H. Local prostaglandin e2 in patients with oral malignancies undergoing chemo- and radiotherapy. J Craniomaxillofac Surg
16, 371–374 (1988). 79. Labar B, Mrsic M, Pavletic Z et al. Prostaglandin e2 for prophylaxis of oral mucositis following
bmt. Bone Marrow Transplant 11, 379–382 (1993). 80. Abdelaal AS, Barker DS, Fergusson MM. Treatment for irradiation-induced mucositis. Lancet 1,
97 (1989). 81. Leborgne JH, Leborgne F, Zubizarreta E, Ortega B, Mezzera J. Corticosteroids and radiation
mucositis in head and neck cancer. A double-blind placebo-controlled randomized trial. Radiother Oncol 47, 145–148 (1998).
82. Epstein JB, Stevenson-Moore P. Benzydamine hydrochloride in prevention and management of pain in oral mucositis associated with radiation therapy. Oral Surg Oral Med Oral Pathol 62, 145–148 (1986).
83. Samaranayake LP, Robertson AG, Farlane TWM. The effect of chlorhexidine and benzydaminemouthwashes on mucositis induced by therapeutic irradiation. Clin Radiol 39, 291-294 (1988).
84. Epstein JB, Stevenson-Moore P, Jackson S, Mohamed JH, Spinelli JJ. Prevention of oral mucositis in radiation therapy: A controlled study with benzydamine hydrochloride rinse. Int J Radiat
Oncol Biol Phys 16, 1571–1575 (1989). 85. Cheng KKF, Yuen JKT. A pilot study of chlorhexidine and benzydamine oral rinses for the
prevention and treatment of irradiation mucositis in patients with head and neck cancer. Cancer
Nurs 29, 423–430 (2006). 86. Kazemian A, Kamian S, Aghili M, Hashemi FA, Haddad P. Benzydamine for prophylaxis of
radiation-induced oral mucositis in head and neck cancers: A double-blind placebo-controlled randomized clinical trial. Eur J Cancer Care 18, 174–178 (2009).
87. Kim JH, Chu F, Lakshmi V, Houde R. A clinical study of benzydamine for the treatment of radiotherapy-induced mucositis of the oropharynx. Int J Tissue React 7, 215–218 (1985).
88. Putwatana P, Sanmanowong P, Oonprasertpong L, Junda T, Pitiporn S, Narkwong L. Relief of radiation-induced oral mucositis in head and neck cancer. Cancer Nurs 32, 82–87 (2009).
89. Kim JH, Chu FC, Lakshmi V, Houde R. Benzydamine hcl, a new agent for the treatment of radiation mucositis of the oropharynx. Am J Clin Oncol 9, 132–134 (1986).
90. Prada A, Chiesa F. Effects of benzydamine on the oral mucositis during antineoplastic radiotherapy and/or intra-arterial chemotherapy. Int J Tissue React 9, 115–119 (1987).
91. Cheng KK, Chang AM. Palliation of oral mucositis symptoms in pediatric patients treated with cancer chemotherapy. Cancer Nurs 26(6), 476-484 (2003).
92. Cheng KKF. Children’s acceptance and tolerance of chlorhexidine and benzydamine oral rinses in the treatment of chemotherapy-induced oropharyngeal mucositis. European Journal of
Oncology Nursing 8, 341–349 (2004). 93. Cheng KKF, Chang AM, Yuen MP. Prevention of oral mucositis in paediatric patients treated with
chemotherapy: A randomised crossover trial comparing two protocols of oral care. European
Journal of Cancer 40, 1208–1216 (2004). 94. Sonis ST, Clairmont F, Lockhart PB, Connolly SF. Benzydamine hcl in the management of
chemotherapy-induced mucositis i. Pilot study. J Oral Med 40, 67–71 (1985). 95. Schubert MM, Newton RE. The use of benzydamine hcl for the management of cancer therapy-
induced mucositis: Preliminary report of a multicentre study. Int J Tissue React 9, 99–103 (1987). 96. Hanson WR, Marks JE, Reddy SP, S Simon , Mihalo WE, Tova Y. Protection from radiation-
induced oral mucositis by a mouth rinse containing the prostaglandin e1 analog, misoprostol: A placebo controlled double blind clinical trial. Adv ExpMed Biol 400B, 811–818 (1997).
97. Turhal N, Erdal S, Karacay S. Efficacy of treatment to relieve mucositis-induced discomfort. Support Care Cancer 8, 55–58 (2000).
98. Dodd MJ, Dibble SL, Miaskowski C et al. Randomized clinical trial of the effectiveness of 3 commonly used mouthwashes to treat chemotherapy-induced mucositis. Oral Surg Oral Med
Oral Pathol Oral Radiol Endod 90, 39–47 (2000). 99. Pillsbury HC, Webster WP, Rosenman J. Prostaglandin inhibitor and radiotherapy in advanced
head and neck cancers. Arch Otolaryngol Head Neck Surg 112, 552–553 (1986). 100. Osaki T, Ueta E, Yoneda K, Hirota J, Yamamoto T. Prophylaxis of oral mucositis associated with
chemoradiotherapy for oral carcinoma by azelastine hydrochloride (azelastine) with other antioxidants. Head Neck 16, 331–339 (1994).
101. Rymes N, Glick L, Holmes JA. Opical mesalazine in the treatment of chemotherapy and radiotherapy-induced oral mucositis. Bone Marrow Transplant 18, 484 (1996).
102. Sorensen JB, Skovsgaard T, Bork E, Damstrup L, Ingeberg S. Double–blind, placebo–controlled, randomized study of chlorhexidine prophylaxis for 5–fluorouracil–based chemotherapy–induced oral mucositis with nonblinded randomized comparison to oral cooling (cryotherapy) in gastrointestinal malignancies. Cancer 112, 1600–1606 (2008).
103. Pitten FA, Kiefer T, Buth C, Doelken G, Kramer A. Do cancer patients with chemotherapy-induced leukopenia benefit from an antiseptic chlorohexidine-based oral rines? A double-blind, block-randomized, controlled study. journal of hospital infection 53, 283-291 (2003).
104. Mehdipour M, Taghavi-Zenoz A, Asvadi-Kermani I, Hosseinpour A. A comparison between zinc sulfate and chlorhexidine gluconate mouthwashes in the prevention of chemotherapy-induced oral mucositis. DARU 19(1), 71-73 (2011).
105. Roopashri G, Jayanthi K, Guruprasad R. Efficacy of benzydamine hydrochloride, chlorhexidine, and povidone iodine in the treatment of oral mucositis among patients undergoing radiotherapy in head and neck malignancies: A drug trail. Contemporary Clinical Dentistry 2(1), 8-12 (2011).
106. Costa EMMDB, Fernandes MZ, Quinderé LB, Souza LBD, Pinto LP. Evaluation of an oral preventive protocol in children with acute lymphoblastic leukemia. Pesqui Odontol Bra 17(2), 147-150 (2003).
107. Antunes HS, Ferreira EMDS, Faria LMDD et al. Streptococcal bacteremia in patients submitted to hematopoietic stem cell transplantation: The role of tooth brushing and use of chlorhexidine. Med Oral Patol Oral Cir Bucal 15(2), 303-309 (2010).
108. Bhatt V, Vendrell N, Nau K, Crumb D, Roy V. Implementation of a standardized protocol for prevention and management of oral mucositis in patients undergoing hematopoietic cell transplantation. Oncol Pharm Practice 16, 195–204 (2010).
109. Ferretti GA, Ash RC, Brown AT. Control of oral mucositis and candidiasis in marrow transplantation: A prospective, double-blind trial of chlorhexidine digluconate oral rinse. Bone
Marrow Transplant 3, 483–493 (1988). 110. Ferretti GA, Ash RC, Brown AT, Largent BM, Kaplan A, Lillich TT. Chlorhexidine for prophylaxis
against oral infections and associated complications in patients receiving bone marrow transplants. J Am Dent Assoc 114, 461–467 (1987).
111. Ferretti GA, Raybould TP, Brown AT. Chlorhexidine prophylaxis for chemotherapy- and radiotherapy-induced stomatitis: A randomized double-blind trial. Oral Surg Oral Med Oral
Pathol 69, 331–338 (1990). 112. Foote RL, Loprinzi CL, Frank AR et al. Randomized trial of a chlorhexidine mouthwash for
alleviation of radiation-induced mucositis. J Clin Oncol 12, 2630–2633 (1994). 113. Spijkervet FK, Saene HKV, Saene JJV, Panders AK, Vermey A, Mehta DM. Mucositis prevention by
selective elimination of oral flora in irradiated head and neck cancer patients. J Oral Pathol Med
19, 486–489 (1990). 114. Weisdorf DJ, Bostrom B, Raether D. Oropharyngeal mucositis complicating bone marrow
transplantation: Prognostic factors and the effect of chlorhexidine mouth rinse. Bone Marrow
Transplant 4, 89–95 (1989). 115. Madan PD, Sequeira PS, Shenoy K, Shetty J. The effect of three mouthwashes on radiation-
induced oral mucositis in patients with head and neck malignancies: A randomized control trial. J Cancer Res Ther 4, 3–8 (2008).
116. Rutkauskas JS, Davis JW. Effects of chlorhexidine during immunosuppressive chemotherapy. A preliminary report. Oral Surg Oral Med Oral Pathol 76, 441–448 (1993).
117. Raether D, Walker PO, Bostrum B, Weisdorf D. Effectiveness of oral chlorhexidine for reducing stomatitis in a pediatric bone marrow transplant population. Pediatr Dent 11, 37–42 (1989).
118. Bergmann OJ, Mogensen SC, Ellermann-Eriksen S, Ellegoard J. Ayclovir prophylaxis and fever during remission-induction therapy of patients with acute myeloid leukemia: A randomized, double blind, placebo -controlled trial. J Clin Oncol 15, 2269-2274 (1997).
119. Bubley GJ, Chapman B, Chapman S. Effect of acyclovir on radiation-and chemotherapy-induced mouth lesions. Antimicrob Agents Chemother 33, 862-865 (1989).
120. Eisen D, Essell J, Broun ER, Sigmun D, Devoe M. Clinical utility of oral valacyclovir compared with oral acyclovir for the prevention of herpes simplex virus mucositis following autologous bone marrow transplantation or stem cell rescue therapy. Bone Marrow Transplantation 31, 51–55 (2003).
121. Nicolatou-Galitis O, Velegraki A, Sotiropoulou-Lontou A et al. Effect of fluconazole antifungal prophylaxis on oral mucositis in head and neck cancer patients receiving radiotherapy. Support
Care Cancer 14, 44–51 (2006). 122. Corvo R. Effects of fluconazole in the prophylaxis of oropharyngeal candidiasis in patients
undergoing radiotherapy for head and neck tumour: Results from a double-blind placebo-controlled trial. Eur J Cancer Care 17(3), 270–277 (2008).
123. Allison RR, Vongtama V, Vaughan J, Shin KH. Symptomatic acute mucositis can be minimized or prophylaxed by the combination of sucralfate and fluconazole. Cancer Invest 13, 16–22
124. Lefebvrea JL, Domenge C. A comparative study of the efficacy and safety of fluconazole oral suspension and amphotericin b oral suspension in cancer patients with mucositis. Oral Oncology
125. Lashof AMLO, Bock RD, Herbrecht R et al. An open multicentre comparative study of the efficacy, safety and tolerance of fluconazole and itraconazole in the treatment of cancer patients with oropharyngeal candidiasis. European Journal of Cancer 40, 1314–1319 (2004).
126. Epstein JB, Gorsky M, Caldwell J. Fluconazole mouthrinses for oral candidiasis in postirradiation, transplant, and other patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 93, 671-675 (2002).
127. Koc M, Aktas E. Prophylactic treatment of mycotic mucositis in radiotherapy of patients with head and neck cancers. Jpn J Clin Oncol 33(2), 57–60 (2003).
128. Orvain C, Moles-Moreau MP, François S et al. Miconazole mucoadhesive buccal tablet in high-dose therapy with autologous stem cell transplantation (hdt/asct)-induced mucositis. Support
Care Cancer 23, 359–364 (2015). 129. Giles FJ, Miller CB, Hurd DD et al. A phase iii, randomized, double-blind, placebo-controlled,
multinational trial of iseganan for the prevention of oral mucositis in patients receiving stomatotoxic chemotherapy (prompt-ct trial). Leuk Lymphoma 44(7), 1165-1172 (2003 ).
130. Giles FJ, Rodriguez R, Weisdorf D et al. A phase iii, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy. Leukemia Research 28, 559–565 (2004).
131. Yoneda S, Imai S, Hanada N et al. Effects of oral care on development of oral mucositis and microorganisms in patients with esophageal cancer. Jpn J Infect Dis 60(1), 23-28 (2007).
132. Vokurka S, Bystřická E, Koza V et al. The comparative effects of povidone-iodine and normal saline mouthwashes on oral mucositis in patients after high-dose chemotherapy and apbsct- results of a randomized multicentre study. Support Care Cancer 13, 554–558 (2005).
133. Madan-Kumar PD, Sequeira PS, Shenoy K, Shetty J. The effect of three mouthwashes on radiation-induced oral mucositis in patients with head and neck malignancies: A randomized control trial. journal of cancer research and theraputics 4(1), 3-8 (2008).
134. Yuen KY, Woo PC, Tai JW, Lie AK, Luk J, Liang R. Effects of clarithromycin on oral mucositis in bone marrow transplant recipients. Haematologica 86(5), 554-555 (2001).
135. Epstein JB, Vickars L, Spinelli J, Reece D. Efficacy of chlorhexidine and nystatin rinses in prevention of oral complications in leukemia and bone marrow transplantation. Surg Oral Med
Oral Pathol 73, 682–689 (1992). 136. El-Sayed S, Epstein J, Minish E, Burns P, Hay J, Laukkanen E. A pilot study evaluating the safety
and microbiologic efficacy of an economically viable antimicrobial lozenge in patients with head and neck cancer receiving radiation therapy. Head Neck 24, 6–15 (2002).
137. Spijkervet FK, Saene HKV, Saene JJV. Effect of selective elimination of the oral flora on mucositis in irradiated head and neck cancer patients. J Surg Oncol 46, 167–173 (1991).
138. Stokman MA, Spijkervet FK, Burlage FR et al. Oral mucositis and selective elimination of oral flora in head and neck cancer patients receiving radiotherapy: A double-blind randomised clinical trial. Br J Cancer 88(7), 1012-1106 (2003).
139. Symonds RP, Mcilroy V, Khorrami J et al. The reduction of radiation mucositis by selective decontamination antibiotic pastilles: A placebo-controlled double-blind trial. Br J Cancer 74(2), 312-317 (1996).
140. Wijers OB, Levendag PC, Harms ER et al. Mucositis reduction by selective elimination of oral flora in irradiated cancers of the head and neck: A placebo-controlled double-blind randomized study. Int J Radiat Oncol Biol Phys 50(2), 343-352 (2001).
141. Bondi E, Baroni C, Prete A. Local antimicrobial therapy of oral mucositis in paediatric patients undergoing bone marrow transplantation. Oral Oncology 33, 322–326 (1997).
142. Papas A, Clark R, Martuscelli G, Oloughlin K, Johansen E, Miller K. A prospective, randomized trial for the prevention of mucositis in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 31, 705–712 (2003).
143. Wasko-Grabowska A, Rzepecki P, Oborska S et al. Efficiency of supersaturated calcium phosphate mouth rinse treatment in patients receiving high-dose melphalan or beam prior to autologous blood stem cell transplantation: A single-center experience. Transplantation
Proceedings 43(3111–3113), (2011). 144. Miyamoto CT, Wobb J, Micaily B, Li S, Achary MP. A retrospective match controlled study of
supersaturated calcium phosphate oral rinse vs. Supportive care for radiation induced oral mucositis. Journal of Cancer Therapy 3, 630-636 (2012).
145. Svanberg A, Ohrn K, Birgegard G. Caphosol ® mouthwash gives no additional protection against oral mucositis compared to cryotherapy alone in stem cell transplantation. A pilot study. European Journal of Oncology Nursing 19, 50-53 (2015).
146. Rao NG, Trotti A, Kim J et al. Phase ii multicenter trial of caphosol for the reduction of mucositis in patients receiving radiation therapy for head and neck cancer. Oral Oncology 50, 765–769 (2014).
147. Raphael MF, Boer AMD, W.Kollen WJ et al. Caphosol, a therapeutic option in case of cancer therapy-induced oral mucositis in children? Support Care Cancer 22, 3–6 (2014).
148. Pettit L, Sanghera P, Glaholm J, Hartley A. The use of mugard™, caphosol® and episil® in patients undergoing chemoradiotherapy for squamous cell carcinoma of the head and neck. Journal of
Radiotherapy in Practice 13 (2), 218-225 (2014). 149. Graham KM, Pecoraro DA, Ventura M, Meyer CC. Reducing the incidence of stomatitis using a
quality assessment and improvement approach. Cancer Nurs 16, 117–122 (1993). 150. Soga Y, Sugiura Y, Takahashi K et al. Progress of oral care and reduction of oral -a pilot study in a
hematopoietic stem cell transplantation ward. Support Care Cancer 19, 303–307 (2011). 151. Kenny SA. Effect of two oral care protocols on the incidence of stomatitis in hematology
patients. Cancer Nurs 13, 345–353 (1990). 152. Maiya GA, Sagar MS, Fernandes D. Effect of low level helium–neon (he–ne) laser therapy in the
prevention and treatment of radiation induced mucositis in head and neck cancer patients. Indian J Med Res 124, 399–402 (2006).